Summary What is already known about this topic?The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron subvariants in vitro s...Summary What is already known about this topic?The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron subvariants in vitro studies.What is added by this report?This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019(COVID-19)infection in medical personnel for the first time.What are the implications for public health practice?This study provides an effective approach for the public to reduce their risk of COVID-19 infection.The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak.展开更多
目的初步评估探讨核酸筛查模式对献血人群乙型肝炎病毒(hepatitis B virus,HBV)传播残余风险度的影响。方法采用中国大陆执业比对工作组信息管理系统的相关数据,利用NAT单阳性率-窗口期比率数学模型(NAT yield/WP ratio model),对2015—...目的初步评估探讨核酸筛查模式对献血人群乙型肝炎病毒(hepatitis B virus,HBV)传播残余风险度的影响。方法采用中国大陆执业比对工作组信息管理系统的相关数据,利用NAT单阳性率-窗口期比率数学模型(NAT yield/WP ratio model),对2015—2019年度我国18家血液中心的献血人群HBV传播的残余风险度进行趋势分析;同时分析比较2019年18家血液中心的ELISA联合核酸单检/混检(ELISA+ID-NAT/MP-NAT)和ELISA联合核酸混检(ELISA+MP-NAT)2种血液筛查(简称血筛)模式对残余风险度的影响。结果18家血液中心5年的HBV血筛残余风险度总体趋势经趋势卡方检验显示:核酸检测单阳性率趋势χ^(2)=39.42(P<0.01),残余风险度趋势χ^(2)=279.792(P<0.01);ELISA+ID-NAT/MP-NAT和ELISA+MP-NAT 2种不同血筛模式对残余风险度RR的影响差异有显著统计学意义,卡方检验显示χ^(2)=7.4(P<0.01)。结论自2015年我国将核酸检测用于血筛以来,HBV输血传播的残余风险度呈逐年下降趋势,目前主要的2种血筛模式对血液残余风险度有可能造成差别。展开更多
文摘Summary What is already known about this topic?The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron subvariants in vitro studies.What is added by this report?This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019(COVID-19)infection in medical personnel for the first time.What are the implications for public health practice?This study provides an effective approach for the public to reduce their risk of COVID-19 infection.The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak.
文摘目的初步评估探讨核酸筛查模式对献血人群乙型肝炎病毒(hepatitis B virus,HBV)传播残余风险度的影响。方法采用中国大陆执业比对工作组信息管理系统的相关数据,利用NAT单阳性率-窗口期比率数学模型(NAT yield/WP ratio model),对2015—2019年度我国18家血液中心的献血人群HBV传播的残余风险度进行趋势分析;同时分析比较2019年18家血液中心的ELISA联合核酸单检/混检(ELISA+ID-NAT/MP-NAT)和ELISA联合核酸混检(ELISA+MP-NAT)2种血液筛查(简称血筛)模式对残余风险度的影响。结果18家血液中心5年的HBV血筛残余风险度总体趋势经趋势卡方检验显示:核酸检测单阳性率趋势χ^(2)=39.42(P<0.01),残余风险度趋势χ^(2)=279.792(P<0.01);ELISA+ID-NAT/MP-NAT和ELISA+MP-NAT 2种不同血筛模式对残余风险度RR的影响差异有显著统计学意义,卡方检验显示χ^(2)=7.4(P<0.01)。结论自2015年我国将核酸检测用于血筛以来,HBV输血传播的残余风险度呈逐年下降趋势,目前主要的2种血筛模式对血液残余风险度有可能造成差别。